# A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer

> **NCT04031885** · PHASE4 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 4 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Abemaciclib
- **DRUG:** Fulvestrant
- **DRUG:** Standard Chemotherapy

## Key facts

- **NCT ID:** NCT04031885
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-08-14
- **Primary completion:** 2020-08-11
- **Final completion:** 2020-08-11
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Business decision based on the inability to enroll subjects into the trial
- **Last updated:** 2021-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04031885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04031885, "A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04031885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*